Karo Bio io AB has announced today that it has acquired the two companies Apropharm AS and Apropharm AB.
The product portfolio consists of mainly pharmaceutical products in Norway and Sweden. A newly registred product for soar throat, Triolif, has recently become registred and will be launched in September.
The turnover is approximately 50 MSEK with a operating profit of approximately 12 MSEK. Karo Bio is paying approximately 100 MSEK for the acquisition.
“This acquisition is an important step to creating a foundation for the expansion in the Nordic region. We have a number of new Products which will be launched during the coming couple of years,” said Anders Lönner, chairman of Karo Bio.
Source: Karo Bio